Get the Stockscreener App
9.91
23.88%
1.91
Newamsterdam Pharma Company N V stock is traded at $9.91, with a volume of 7,739.
It is up +23.88% in the last 24 hours and up +20.85% over the past month.
NewAmsterdam Pharma Company N.V., a clinical-stage biopharmaceutical company, develops oral and non-statin medicines for patients at high risk of cardiovascular disease. Its lead product candidate is obicetrapib, a next generation, oral, and low-dose cholesteryl ester transfer protein (CETP) inhibitor, that is in four ongoing Phase 3 and Phase 2b clinical trials as both a monotherapy and a combination therapy with ezetimibe for lowering LDL-C and preventing major adverse cardiovascular events (MACE). NewAmsterdam Pharma Company N.V. is headquartered in Naarden, the Netherlands.
See More
Previous Close:
$8.00
Open:
$8.4
24h Volume:
7,739
Relative Volume:
1.89
Market Cap:
$N/A
Revenue:
-
Net Income/Loss:
-
P/E Ratio:
-
EPS:
-
Net Cash Flow:
-
1W Performance:
+11.35%
1M Performance:
+20.85%
6M Performance:
-9.58%
1Y Performance:
+0.00%
1-Day Range:
$8.40
$10.00
1-Week Range:
$7.70
$10.00
52-Week Range:
$2.60
$14.67
Newamsterdam Pharma Company N V Stock (NAMSW) Company Profile
Name
Newamsterdam Pharma Company N V
Sector
Industry
Phone
31 35 206 2971
Address
Gooimeer 2-35, Naarden
Newamsterdam Pharma Company N V Stock (NAMSW) Latest News
(NAMS) Technical Pivots with Risk Controls - Stock Traders Daily
NewAmsterdam Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
NewAmsterdam Pharma to Participate in Upcoming Medical and Investor Conferences in November - 24matins.uk
Needham Initiates Coverage of NewAmsterdam Pharma Company N.V. (NAMS) with Buy Recommendation - MSN
NewAmsterdam Pharma to Restate Prior Financials By Investing.com - Investing.com Australia
NewAmsterdam Pharma to Restate Prior Financials - Investing.com India
(NAMSW) Trading Report - Stock Traders Daily
NewAmsterdam Pharma Breaks Above 200-Day Moving AverageBullish for NAMS - Nasdaq
Brokerages Set NewAmsterdam Pharma (NASDAQ:NAMS) Target Price at $33.80 - MarketBeat
NewAmsterdam Pharma Company N.V. (NAMS) Price Target Increased by 8.93% to 31.11 - MSN
Marshall Wace LLP Decreases Stake in NewAmsterdam Pharma (NASDAQ:NAMS) - MarketBeat
When the Price of (NAMSW) Talks, People Listen - Stock Traders Daily
Millennium Management LLC Has $22.39 Million Stock Holdings in NewAmsterdam Pharma (NASDAQ:NAMS) - MarketBeat
Obicetrapib Positions NewAmsterdam Pharma For Significant Market Growth In Cardiovascular Therapies - Seeking Alpha
NewAmsterdam Pharma executive sells shares worth $707,400 By Investing.com - Investing.com South Africa
NewAmsterdam Pharma executive sells shares worth $707,400 - Investing.com India
NewAmsterdam Pharma (NASDAQ:NAMS) Shares Gap Down to $16.60 - MarketBeat
NewAmsterdam Pharma Company NV (NAMS) rating initates by TD Cowen - Knox Daily
Does NewAmsterdam Pharma Company NV (NAMS) offer a good opportunity for investors? - SETE News
Newamsterdam Pharma exec buys $17,332 in company stock By Investing.com - Investing.com Australia
Newamsterdam Pharma exec buys $17,332 in company stock - Investing.com India
NewAmsterdam Pharma (NASDAQ:NAMS) Sees Strong Trading Volume - MarketBeat
TD Cowen Initiates Coverage of NewAmsterdam Pharma Company N.V. (NAMS) with Buy Recommendation - MSN
Deerfield Management Company L.P. Series C Has $16.70 Million Position in NewAmsterdam Pharma (NASDAQ:NAMS) - MarketBeat
Affinity Asset Advisors LLC Boosts Holdings in NewAmsterdam Pharma (NASDAQ:NAMS) - MarketBeat
Investment opportunity in NewAmsterdam Pharma stock as anticipation builds for BROADWAY results By Investing.com - Investing.com
NewAmsterdam Pharma (NASDAQ:NAMS) Earns "Overweight" Rating from Piper Sandler - MarketBeat
Expert Ratings For NewAmsterdam Pharma - Benzinga
Piper sees ‘attractive buying opportunity’ into NewAmsterdam data - TipRanks
NWF Group Shareholding Structure Altered - TipRanks
'She's A Hardy Filly': Ocean Club Goes All The Way On Front End In Noble Damsel - Paulick Report
Ocean Club Skims to Narrow Victory in Noble Damsel - BloodHorse.com
Ocean Club, in quick turnaround, holds off Five Towns, Breath Away to take Noble Damsel - Daily Racing Form
Trend Tracker for (NAMS) - Stock Traders Daily
Top Bud padlocked in Holland Patent for illegal cannabis - Rome Sentinel
Kenneth Law, who sold poisonous chemical linked to 131 deaths, sued by Ontario teen's parents - CBC.ca
NewAmsterdam Pharma (NASDAQ:NAMS) Receives Consensus Recommendation of "Buy" from Brokerages - MarketBeat
While institutions own 29% of NewAmsterdam Pharma Company N.V. (NASDAQ:NAMS), private equity firms are its largest shareholders with 47% ownership - Yahoo Finance
NewAmsterdam Pharma (NASDAQ:NAMS) Earns "Outperform" Rating from Royal Bank of Canada - MarketBeat
NewAmsterdam Pharma (NASDAQ:NAMS) Short Interest Up 20.7% in August - MarketBeat
NAMSWNewAmsterdam Pharma Company N.V. Warrant Latest Stock News & Market Updates - StockTitan
Buying Buzz: NewAmsterdam Pharma Company NV [NAMS] Chief Executive Officer Davidson Michael H. purchases 5,000 shares of the company – Knox Daily - Knox Daily
NewAmsterdam Pharma to Participate in Upcoming Investor Conferences in September - Yahoo Finance
NewAmsterdam Pharma (NASDAQ:NAMS) Sees Unusually-High Trading Volume - MarketBeat
NewAmsterdam Pharma's Cholesterol Drug To See Blockbuster Sales, Bullish Analyst Sees Massive Upside - Benzinga
NewAmsterdam Pharma (NASDAQ:NAMS) Now Covered by Analysts at Needham & Company LLC - MarketBeat
NewAmsterdam shares hold Buy rating on strong trial data - Investing.com
NewAmsterdam Pharma Company NV (NAMS)’s Market Momentum: Closing Strong at 16.76, Up 3.08 - The Dwinnex
You might want to take a look at NewAmsterdam Pharma Company NV (NAMS) now - SETE News
The Future of NewAmsterdam Pharma Company NV: Analyzing NAMS - The InvestChronicle
NewAmsterdam Pharma Company NV [NAMS] is 47.99% higher this YTD. Is it still time to buy? - The DBT News
Newamsterdam Pharma Company N V Stock (NAMSW) Financials Data
There is no financial data for Newamsterdam Pharma Company N V (NAMSW). Check out other stocks for more information.
Revenue
Net Income
Cash Flow
EPS
1.03%
1.25%
Cap:
|
Volume (24h):